In an effort to strengthen its presence in metabolic dysfunction-associated steatohepatitis (MASH), Madrigal Pharmaceuticals has signed a licensing agreement with Suzhou Ribo Life Science and its subsidiary, Ribocure Pharmaceuticals, to develop six preclinical siRNA programmes for the treatment of MASH. Through the deal, which includes a US$60 M upfront payment and up to US$4.4 B in milestones, Madrigal gains an exclusive license to several preclinical mono- and bispecific siRNA assets leveraging Ribo’s RiboGalStar™ and siRNA modification platforms. The deal marks yet another MASH-focused partnership signed by Madrigal following its recent alliances with CSPC Pharmaceutical Group and Pfizer.